PRNewsWire
03 Aug 2026, 21:45 UTC · 2h ago
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
03 Aug 2026, 21:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
There is an alleged substantial risk to the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy. — Failure to obtain regulatory approval for a lead therapy candidate is a critical negative catalyst for a biotech company's valuation.
-0.90The lawsuit claims Capricor changed its statistical analysis plan for Deramiocel without prior FDA agreement before resubmitting its Biologics License Application. — Unauthorized changes to clinical analysis plans significantly increase the risk of FDA rejection, threatening the company's primary product pipeline.
-0.80Capricor Therapeutics faces a securities fraud class action lawsuit alleging the company made misleading statements regarding the regulatory path for Deramiocel. — Securities litigation and allegations of misleading investors create significant reputational risk and potential financial liabilities.
-0.60Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is the target of a securities fraud class action lawsuit alleging misleading statements regarding clinical data and FDA approval processes.
Mentioned in the context of investors suffering losses and a potential legal deadline.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Business Wire
4h ago
